In 670 healthy 15–25-year-olds, the quadrivalent HPV vaccine Papilloguard (with AS04 adjuvant) was non-inferior to Gardasil for antibody responses to HPV 6, 11, 16 and 18 at day 210. Higher responses were not prespecified, and local reactions were more frequent.
RCTn = 670
Mardani et al. Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial